Bacterial bunker-busters: Novel Immunotherapeutics against Pneumonic Plague 2253158

M Michael Davies (Lexicon Pharmaceuticals, Bridgewater, New Jersey, United States) T Taloria Wheeler (USAMRIID) C Christopher Klimko (USAMRIID) J Jennifer Dankmeyer (USAMRIID) N Nathaniel Rill (USAMRIID) W Wendy Webster-Zahnow (USAMRIID) A Andre Swamotz (USAMRIID) Y Yunuen Hernandez-Viezcas (USAMRIID) C Carlos Rodriguez A Alfonso Arballo (Eitr Biologics, Inc) R Rudo Simeon (Eitr Biologics, Inc) J Ju Qiu C Crystal Moyer (Eitr Biologics, Inc) C Christopher Cote Z Zachary Bornholdt (Eitr Biologics, Inc) S Sergei Biryukov (USAMRIID)

Abstract

Abstract Introduction Yersinia pestis (Yp) is a gram-negative bacillus that causes plague in humans and animals and is endemic in Africa, Asia, and the Americas. When aerosolized, bacterium can cause an acute, often fatal disease that requires antibiotic intervention within 24hr of exposure. Antibodies have been previously raised against two protective antigens, F1 and LcrV, unfortunately Yp is able to circumvent these countermeasures. Methods To expand the breadth of protective targets we generated cow anti-sera against four novel antigens with potential induction of bovine exclusive ultralong CDR H3 antibodies. Cows were administered six doses of Pla, LptED, Ail and BamA, 3-4 weeks apart and antibody titers were evaluated throughout the duration of the study. Results Functional activity of anti-sera was evaluated utilizing gentamicin protection assay, by enumeration of internalized Yp by RAW cells in the presence or absence of complement. A prominent anti-LptED antibody response developed early during the course of vaccination, followed by anti-Pla, -Ail and -BamA. The number of RAW cells that internalized viable Yp was considerably lower in the presence of fresh or C8 repleted serum relative to heat inactivated or C8 depleted sera. Conclusion The inhibitory properties of cow anti-sera against four Yp antigens will enable identification of novel protective targets that will be used to produce additional countermeasures, especially if they stem from the ultralong CDR H3 repertoire. Funding Source DTRA-JSTO Topic Categories Vaccines and Immunotherapy (VAC)

Article Details

Volume / Issue Vol. 215, Issue Supplement_1
Published August 01, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (16)

M

Michael Davies

Lexicon Pharmaceuticals, Bridgewater, New Jersey, United States

T

Taloria Wheeler

USAMRIID

C

Christopher Klimko

USAMRIID

J

Jennifer Dankmeyer

USAMRIID

N

Nathaniel Rill

USAMRIID

W

Wendy Webster-Zahnow

USAMRIID

A

Andre Swamotz

USAMRIID

Y

Yunuen Hernandez-Viezcas

USAMRIID

C

Carlos Rodriguez

A

Alfonso Arballo

Eitr Biologics, Inc

R

Rudo Simeon

Eitr Biologics, Inc

J

Ju Qiu

C

Crystal Moyer

Eitr Biologics, Inc

C

Christopher Cote

Z

Zachary Bornholdt

Eitr Biologics, Inc

S

Sergei Biryukov

USAMRIID